Your browser doesn't support javascript.
loading
S-ketamine in patient-controlled analgesia reduces opioid consumption in a dose-dependent manner after major lumbar fusion surgery: A randomized, double-blind, placebo-controlled clinical trial.
Brinck, Elina C V; Virtanen, Taru; Mäkelä, Sanna; Soini, Venla; Hynninen, Ville-Veikko; Mulo, Jukka; Savolainen, Urmas; Rantakokko, Juho; Maisniemi, Kreu; Liukas, Antti; Olkkola, Klaus T; Kontinen, Vesa; Tarkkila, Pekka; Peltoniemi, Marko; Saari, Teijo I.
Afiliação
  • Brinck ECV; Division of Anaesthesiology, Intensive Care and Pain Medicine, Department of Anaesthesiology, Töölö Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Virtanen T; Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Mäkelä S; Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland.
  • Soini V; Division of Perioperative Services, Intensive Care Medicine and Pain Management; Turku University Hospital, Turku, Finland.
  • Hynninen VV; Division of the musculoskeletal system at Turku University Hospital, Department of Orthopaedics, Turku University Hospital, University of Turku, Turku, Finland.
  • Mulo J; Division of Perioperative Services, Intensive Care Medicine and Pain Management; Turku University Hospital, Turku, Finland.
  • Savolainen U; Division of Perioperative Services, Intensive Care Medicine and Pain Management; Turku University Hospital, Turku, Finland.
  • Rantakokko J; Division of Perioperative Services, Intensive Care Medicine and Pain Management; Turku University Hospital, Turku, Finland.
  • Maisniemi K; Division of the musculoskeletal system at Turku University Hospital, Department of Orthopaedics, Turku University Hospital, University of Turku, Turku, Finland.
  • Liukas A; Division of Anaesthesiology, Intensive Care and Pain Medicine, Department of Anaesthesiology, Töölö Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Olkkola KT; Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland.
  • Kontinen V; Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Tarkkila P; Division of Anaesthesiology, Intensive Care and Pain Medicine, Department of Anaesthesiology, Jorvi Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.
  • Peltoniemi M; Division of Anaesthesiology, Intensive Care and Pain Medicine, Department of Anaesthesiology, Töölö Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Saari TI; Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland.
PLoS One ; 16(6): e0252626, 2021.
Article em En | MEDLINE | ID: mdl-34097713
ABSTRACT

BACKGROUND:

Spinal fusion surgery causes severe pain. Strong opioids, commonly used as postoperative analgesics, may have unwanted side effects. S-ketamine may be an effective analgesic adjuvant in opioid patient-controlled analgesia (PCA). However, the optimal adjunct S-ketamine dose to reduce postoperative opioid consumption is still unknown.

METHODS:

We randomized 107 patients at two tertiary hospitals in a double-blinded, placebo-controlled clinical trial of adults undergoing major lumbar spinal fusion surgery. Patients were randomly allocated to four groups in order to compare the effects of three different doses of adjunct S-ketamine (0.25, 0.5, and 0.75 mg ml-1) or placebo on postoperative analgesia in oxycodone PCA. Study drugs were administered for 24 hours postoperative after which oxycodone-PCA was continued for further 48 hours. Our primary outcome was cumulative oxycodone consumption at 24 hours after surgery.

RESULTS:

Of the 100 patients analyzed, patients receiving 0.75 mg ml-1 S-ketamine in oxycodone PCA needed 25% less oxycodone at 24 h postoperatively (61.2 mg) compared with patients receiving 0.5 mg ml-1 (74.7 mg) or 0.25 mg ml-1 (74.1 mg) S-ketamine in oxycodone or oxycodone alone (81.9 mg) (mean difference -20.6 mg; 95% confidence interval [CI] -41 to -0.20; P = 0.048). A beneficial effect in mean change of pain intensity at rest was seen in the group receiving 0.75 mg ml-1 S-ketamine in oxycodone PCA compared with patients receiving lower ketamine doses or oxycodone alone (standardized effect size 0.17, 95% CI 0.013-0.32, P = 0.033). The occurrence of adverse events was similar among the groups.

CONCLUSIONS:

Oxycodone PCA containing S-ketamine as an adjunct at a ratio of 1 0.75 decreased cumulative oxycodone consumption at 24 h after major lumbar spinal fusion surgery without additional adverse effects.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxicodona / Fusão Vertebral / Analgesia Controlada pelo Paciente / Ketamina / Vértebras Lombares Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxicodona / Fusão Vertebral / Analgesia Controlada pelo Paciente / Ketamina / Vértebras Lombares Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article